Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants
Executive Summary
The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Roche’s TIGIT data leak; Regeneron gets important US approvals; COVID subvariant vaccine progress; Pfizer’s RSV vaccine extended approval; and Japan recommends lecanemab for Alzheimer’s.
Pfizer Cost Improvement Program Depends On COVID Outlook
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.
Sanofi/AstraZeneca Win Beyfortus Approval To Prevent RSV In US Infants
Sanofi, which leads commercialization under its 2017 deal with AstraZeneca, may soon compete with a maternal RSV vaccine from Pfizer, but the US may have room for only one infant-protecting option.